Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

33.58
-1.7000-4.82%
Pre-market: 32.52-1.0600-3.16%05:45 EDT
Volume:795.94K
Turnover:26.90M
Market Cap:2.18B
PE:-11.26
High:35.32
Open:34.48
Low:33.47
Close:35.28
Loading ...

We're Not Very Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Rate

Simply Wall St.
·
28 Feb

Kymera Therapeutics: Promising Developments and Strategic Positioning Make It a Compelling Buy

TIPRANKS
·
28 Feb

Kymera Therapeutics Inc (KYMR) Q4 2024 Earnings Call Highlights: Strategic Collaborations and ...

GuruFocus.com
·
28 Feb

Kymera Therapeutics Reports 2024 Financial Results and Pipeline Progress

TIPRANKS
·
28 Feb

Kymera Therapeutics (KYMR) Receives a Buy from TD Cowen

TIPRANKS
·
28 Feb

Kymera Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Feb

Stock Track | Kymera Therapeutics Plummets 7.27% in Early Trading on Disappointing Q4 Results

Stock Track
·
27 Feb

Kymera Therapeutics Q4 Net Loss Widens, Collaboration Revenue Falls

MT Newswires Live
·
27 Feb

Kymera Therapeutics, Inc. (KYMR) Reports Q4 Loss, Misses Revenue Estimates

Zacks
·
27 Feb

Earnings Flash (KYMR) Kymera Therapeutics Posts Q4 Revenue $7.4M, vs. FactSet Est of $14.4M

MT Newswires Live
·
27 Feb

Kymera Therapeutics reports Q4 EPS (88c), consensus (79c)

TIPRANKS
·
27 Feb

Kymera Therapeutics Q4 2024 GAAP EPS $(0.88) Misses $(0.78) Estimate, Sales $7.39M Miss $11.82M Estimate

Benzinga
·
27 Feb

BRIEF-Kymera Therapeutics Q4 EPS USD -0.88 Vs. IBES Estimate USD -0.77

Reuters
·
27 Feb

Kymera Therapeutics Q4 EPS USD -0.88 VS. Ibes Estimate USD -0.77

THOMSON REUTERS
·
27 Feb

Kymera Therapeutics: Well-Capitalized With $851 Mln in Cash as of Dec 31, 2024, and Runway Into Mid-2027

THOMSON REUTERS
·
27 Feb

Kymera Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update

GlobeNewswire
·
27 Feb

Kymera Therapeutics Inc expected to post a loss of 77 cents a share - Earnings Preview

Reuters
·
25 Feb

Kymera Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results on February 27

GlobeNewswire
·
20 Feb

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
20 Feb

Naya Biosciences Announces Nomination of New Board Members

THOMSON REUTERS
·
19 Feb